Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212

被引:152
作者
Croxford, JL
Miller, SD
机构
[1] Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA
[2] Northwestern Univ, Sch Med, Interdepartmental Immunobiol Ctr, Chicago, IL 60611 USA
关键词
D O I
10.1172/JCI200317652
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Theiler murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) is a mouse model of chronic-progressive multiple sclerosis (MS) characterized by Th1-mediated CNS demyelination and spastic hindlimb paralysis. Existing MS therapies reduce relapse rates in 30% of relapsing-remitting MS patients, but are ineffective in chronic-progressive disease, and their effects on disability progression are unclear. Experimental studies demonstrate cannabinoids are useful for symptomatic treatment of spasticity and tremor in chronic-relapsing experimental autoimmune encephalomyelitis. Cannabinoids, however, have reported immunosuppressive properties. We show that the cannabinoid receptor agonist, R(+)WIN55,212, ameliorates progression of clinical disease symptoms in mice with preexisting TMEV-IDD. Amelioration of clinical disease is associated with downregulation of both virus and myelin epitope-specific Th1 effector functions (delayed-type hypersensitivity and IFN-gamma production) and the inhibition of CNS mRNA expression coding for the proinflammatory cytokines, TNF-alpha, IL1-beta, and IL-6. Clinical trials investigating the therapeutic potential of cannabinoids for the symptomatic treatment of MS are ongoing, and this study demonstrates that they may also have potent immunoregulatory properties.
引用
收藏
页码:1231 / 1240
页数:10
相关论文
共 56 条
[1]   Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis [J].
Achiron, A ;
Miron, S ;
Lavie, V ;
Margalit, R ;
Biegon, A .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 102 (01) :26-31
[2]  
AGURELL S, 1986, PHARMACOL REV, V38, P21
[3]   A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis -: Inflammation versus degeneration [J].
Ahmed, Z ;
Doward, AI ;
Pryce, G ;
Taylor, DL ;
Pocock, JM ;
Leonard, JP ;
Baker, D ;
Cuzner, ML .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (05) :1577-1586
[4]   Endocannabinoids control spasticity in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Makriyannis, A ;
Khanolkar, A ;
Layward, L ;
Fezza, F ;
Bisogno, T ;
Di Marzo, V .
FASEB JOURNAL, 2001, 15 (02) :300-302
[5]   Cannabinoids control spasticity and tremor in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Huffman, JW ;
Layward, L .
NATURE, 2000, 404 (6773) :84-87
[6]  
Begolka WS, 1998, J IMMUNOL, V161, P4437
[7]   Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis [J].
Berrendero, F ;
Sánchez, A ;
Cabranes, A ;
Puerta, C ;
Ramos, JA ;
García-Merino, A ;
Fernández-Ruiz, J .
SYNAPSE, 2001, 41 (03) :195-202
[8]   A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].
Bouaboula, M ;
Perrachon, S ;
Milligan, L ;
Canat, X ;
RinaldiCarmona, M ;
Portier, M ;
Barth, F ;
Calandra, B ;
Pecceu, F ;
Lupker, J ;
Maffrand, JP ;
LeFur, G ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339
[9]   Eating well [J].
Brooksbank, C .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) :83-83
[10]  
CABRAL GA, 1986, P SOC EXP BIOL MED, V181, P305